Quantitative Proteomics Analysis Integrated with Microarray Data Reveals That Extracellular Matrix Proteins, Catenins, and P53 Binding Protein 1 Are Important for Chemotherapy Response in Ovarian Cancers
Authors:
- 1 August 2009
- journal article
- research article
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 13 (4) , 345-354
Abstract
Chemotherapy with carboplatin and paclitaxel is the standard treatment for ovarian cancer patients. Although most patients initially respond to this treatment, few are cured. Resistance to chemotherapy is the major cause of treatment failure. We applied a quantitative proteomic approach based on ICAT/MS/MS technology to analyze tissues harvested at primary debulking surgery before the initiation of combination chemotherapy in order to identify potential naive or intrinsic chemotherapy response proteins in ovarian cancers. We identified 44 proteins that are overexpressed, and 34 proteins that are underexpressed in the chemosensitive tissue compared to the chemoresistant tissue. The overexpressed proteins identified in the chemoresistant tissue include 10 proteins (25.6%) belonging to the extracellular matrix (ECM), including decorin, versican, basigin (CD147), fibulin-1, extracellular matrix protein 1, biglycan, fibronectin 1, dermatopontin, alpha-cardiac actin (smooth muscle actin), and an EGF-containing fibulin-like extracellular matrix protein 1. Interesting proteins identified as overexpressed in the chemosensitive tissue include gamma-catenin (junction plakoglobin) and delta-catenin, tumor suppressor p53-binding protein 1 (53BP1), insulin-like growth factor-binding protein 2 (IGFBP2), proliferating cell nuclear antigen (PCNA), annexin A11, and 53 kDa selenium binding protein 1. Integrative analysis with expression profiling data of eight chemoresistant tissues and 13 chemosensitive tissues revealed that 16 proteins showed consistent changes at both the protein and the RNA levels. These include P53 binding protein 1, catenin delta 1 and plakoglobin, EGF-containing fibulin-like extracellular matrix protein 1 and voltage-dependent anion-selective channel protein 1. Our results suggest that chemotherapy response may be determined by multiple and complex system properties involving extracellular–matrix, cell adhesion and junction proteins.Keywords
This publication has 40 references indexed in Scilit:
- Perspective: A Program to Improve Protein Biomarker Discovery for CancerJournal of Proteome Research, 2005
- Search for Cancer Markers from Endometrial Tissues Using Differentially Labeled Tags iTRAQ and cICAT with Multidimensional Liquid Chromatography and Tandem Mass SpectrometryJournal of Proteome Research, 2005
- Decreased Expression of 14-3-3σ Is Associated with Advanced Disease in Human Epithelial Ovarian CancerClinical Cancer Research, 2004
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of ActionCurrent Cancer Drug Targets, 2003
- Mass spectrometry-based proteomicsNature, 2003
- EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinomaClinical & Experimental Metastasis, 2003
- E-cadherin and ?-, ?-, and ?-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusionsThe Journal of Pathology, 2000
- An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein databaseJournal of the American Society for Mass Spectrometry, 1994
- Molecular cloning and amino acid sequence of human plakoglobin, the common junctional plaque protein.Proceedings of the National Academy of Sciences, 1989